Hybridoma cell strain, chikungunya virus monoclonal antibody as well as preparation method and application of chikungunya virus monoclonal antibody

By preparing the chikungunya virus monoclonal antibody hybridoma cell line CHIKV mAb 9G8, the challenges of chikungunya virus diagnosis and treatment have been solved, achieving efficient and highly specific detection and neutralization effects, which are suitable for the diagnosis and treatment of chikungunya virus.

CN118956771AInactive Publication Date: 2024-11-15SOUTH CHINA AGRICULTURAL UNIVERSITY +1
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202410500739.2
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-04-24
Publication Date
2024-11-15
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Existing technologies are insufficient for effectively diagnosing chikungunya virus infection, and the lack of specific treatments and vaccines leads to frequent misdiagnosis and missed diagnosis. Furthermore, laboratory testing methods are difficult to promote in developing countries.

Method used

The chikungunya virus monoclonal antibody hybridoma cell line CHIKV mAb 9G8 was prepared using cell electrofusion technology. Highly efficient and specific monoclonal antibodies were obtained by immunizing BALB/c mice, cell fusion, screening and purification, and used for ELISA, indirect immunofluorescence and neutralization detection.

Benefits of technology

It provides highly efficient and specific monoclonal antibodies for the diagnosis and neutralization of Chikungunya virus, supporting diagnostic, quarantine, and epidemiological investigations, and is suitable for simple testing in developing countries.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118956771A_ABST
    Figure CN118956771A_ABST
Patent Text Reader

Abstract

The invention discloses a hybridoma cell strain, a chikungunya virus monoclonal antibody as well as a preparation method and application of the chikungunya virus monoclonal antibody. The chikungunya virus monoclonal antibody is secreted by a hybridoma cell strain CHIKV mAb 9G8, the hybridoma cell strain is preserved in the China Center for Type Culture Collection (the address is Wuhan University, Wuhan, China), the preservation number is CCTCC NO: C2024122, and the preservation date is April 23, 2024. The monoclonal antibody generated by the hybridoma cell strain 9G8 has high specificity and high affinity to the chikungunya virus, can effectively neutralize the chikungunya virus, and has a good neutralizing effect. The biological characteristics of the chikungunya virus neutralizing antibody are identified, so that a foundation is laid for researching the action mechanism of the chikungunya virus neutralizing antibody and developing clinical medicines in the future.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of cell engineering technology, and in particular to a hybridoma cell line and a monoclonal antibody produced by the hybridoma cell line and a preparation method and application thereof, which can be used for detecting and / or neutralizing chikungunya virus. Background Art

[0002] Chikungunya virus (CHIKV) is a single-stranded positive-sense RNA virus belonging to the genus Alphavirus of the family Togaviridae. It is mainly transmitted among humans through the bites of Aedes aegypti and Aedes albopictus. The length of the CHIKV genome is about 11.8 Kb. Four genotypes have been identified based on the E1 envelope glycoprotein sequence: West Africa, East Africa / Central Africa / South Africa (ECSA), Asia, and Indian Ocean lineages (IOL). Infection with CHIKV can cause chikungunya fever, with clinical manifestations of fever, rash, myalgia, and arthralgia, among which arthralgia can last for months to years. There is currently no specific treatment or vaccine. With the influence of global climate change and human activities, the spread of CHIKV is also expanding, causing serious social and economic losses. In recent years, there have been many reports of imported cases in my country, and the vectors of CHIKV are also distributed in my country. Therefore, CHIKV is an insect-borne virus that poses a potential threat to the biosafety of southern my country.

[0004] The main symptoms of CHIKV infection are fever, headache (about 70% of patients), nausea, vomiting (about 60% of patients), rash (about 60% of patients) and severe muscle and joint pain (about 40% of patients). Chikungunya fever is rarely fatal, and most symptoms can be relieved within a few weeks; however, some patients' joint pain will recur or last for months to years, and in severe cases lead to joint deformities. This not only has a serious impact on the lives of patients, but also brings huge epidemic prevention and control challenges and economic burdens to the country and society. Currently, the Centers for Disease Control and Prevention recommends the use of acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs) to relieve CHIKV symptoms, but there is currently no effective treatment or vaccine available.

[0005] The diagnosis of CHIKV is still a challenge, because CHIKV infection has no typical clinical symptoms and is difficult to distinguish from dengue and Zika virus infections. In areas where dengue and Zika viruses are prevalent, the similarity of clinical symptoms is likely to lead to misdiagnosis and missed diagnosis of CHIKV infection. Due to the difficulty of clinical diagnosis, laboratory detection methods for CHIKV are currently essential for accurate diagnosis. Laboratory diagnostic detection techniques mainly include virus isolation, serological detection, and molecular biological detection. These detection methods have good sensitivity and specificity and are commonly used technical means in diagnostic testing. Among them, the RT-PCR method requires well-trained operators and advanced laboratory equipment. For developing countries where CHIKV is prevalent, this method is difficult to promote. Therefore, most developing countries use serological diagnosis methods because serological diagnosis methods are low-cost and easy to operate, but there are cross-reactions between viruses that make it difficult to ensure the accuracy of diagnosis.

[0006] After being infected with Chikungunya virus, the body will produce specific antibodies. Neutralizing monoclonal antibodies can neutralize free virus particles, play a protective role in preventing virus transmission, and can be used for virus prevention and treatment. The monoclonal antibodies obtained in this study have high titers, strong specificity, and significant neutralizing effects, providing technical reserves for the study of neutralizing antibodies against Chikungunya virus. Summary of the invention

[0007] The technical problem solved by the present invention is to overcome the deficiencies of the above-mentioned prior art and provide a chikungunya virus monoclonal antibody hybridoma cell line CHIKV mAb 9G8 and its monoclonal antibody. The monoclonal antibody secreted by the hybridoma cell line of the present invention can be used for biological diagnosis of chikungunya virus including ELISA (enzyme-linked immunosorbent assay), indirect immunofluorescence and neutralization detection.

[0008] The first aspect of the present invention is to provide a chikungunya virus monoclonal antibody hybridoma cell line CHIKVmAb9G8 (Hybridoma cell line CHIKV mAb 9G8, hereinafter referred to as 9G8), which has been deposited in the China Center for Type Culture Collection on April 23, 2024, with a deposit number of CCTCC NO: C2024122, and the deposit address is Wuhan University, Wuhan, China.

[0009] The second aspect of the present invention is to provide a monoclonal antibody against chikungunya virus, which is secreted and produced by the hybridoma cell line 9G8. The monoclonal antibody against chikungunya virus of the present invention is obtained by using the brain of Kunming suckling mice to amplify chikungunya virus and then diluting it in PBS to immunize BALB / c mice as an antigen, and using cell electrofusion technology to obtain the hybridoma cell line 9G8 that produces the antibody, and the antibody secreted by the hybridoma cell is IgG2a type.

[0010] The third aspect of the present invention is to provide a method for preparing a monoclonal antibody against Chikungunya virus as described in the second aspect of the present invention, comprising the following steps:

[0011] (1) BALB / c mice are immunized with Chikungunya virus to obtain immune BALB / c mice;

[0012] (2) Spleen cells of immunized mice were taken and fused with mouse myeloma cells SP2 / 0. After fusion, the cells were selectively cultured in HAT selection medium, positive clones were screened by indirect immunofluorescence method, and hybridoma cells in positive wells were cloned and cultured by limiting dilution method until the antibody positivity rate of cloned cells reached 100%, thereby obtaining hybridoma cell lines;

[0013] (3) The hybridoma cell line obtained in step (2) is transplanted into the peritoneal cavity of mice for culture, the ascites is collected, and the purified monoclonal antibody is obtained by the caprylic acid ammonium sulfate method and affinity chromatography.

[0014] The fourth aspect of the present invention provides the use of the monoclonal antibody against chikungunya virus as described in the second aspect of the present invention or the monoclonal antibody prepared by the preparation method described in the third aspect of the present invention in preparing a reagent for detecting chikungunya virus or in preparing a reagent for diagnosing and / or prognosing chikungunya disease.

[0015] The fifth aspect of the present invention is to provide a reagent for detecting Chikungunya virus, wherein the reagent comprises the Chikungunya virus monoclonal antibody as described in the second aspect of the present invention or the monoclonal antibody prepared by the preparation method described in the third aspect of the present invention.

[0016] The sixth aspect of the present invention is to provide a reagent for diagnosing and / or prognosticating chikungunya fever, wherein the reagent comprises the chikungunya virus monoclonal antibody as described in the second aspect of the present invention or the monoclonal antibody prepared by the preparation method as described in the third aspect of the present invention.

[0017] The seventh aspect of the present invention provides the use of the monoclonal antibody to Chikungunya virus as described in the second aspect of the present invention or the monoclonal antibody prepared by the preparation method described in the third aspect of the present invention in the preparation of a preparation for treating Chikungunya fever.

[0018] The eighth aspect of the present invention is to provide a biological preparation for treating Chikungunya fever, wherein the preparation comprises the Chikungunya virus monoclonal antibody as described in the second aspect of the present invention or the monoclonal antibody prepared by the preparation method as described in the third aspect of the present invention.

[0019] The present invention obtains the chikungunya virus monoclonal antibody hybridoma cell line 9G8 and its monoclonal antibody by the following specific method:

[0020] (1) Virus rejuvenation

[0021] The Chikungunya virus liquid preserved in the laboratory was diluted 100 times and inoculated into the brain of 3-day-old Kunming suckling mice at a dose of 20 μL / mouse. The suckling mice were observed for symptoms of hunched back, hind limb paralysis, and decreased activity. When the suckling mice were dying, they were killed, and the brains were dissected and taken out. Each brain was fully ground with 1 mL of PBS, and the supernatant was centrifuged to obtain the Chikungunya virus liquid rejuvenated by the mouse brain.

[0022] (2) Immunization of BALB / c mice

[0023] In order to obtain the best immunization effect, the Chikungunya virus liquid and Freund's adjuvant need to be fully mixed and emulsified before immunization. Freund's complete adjuvant is used for the first immunization, and Freund's incomplete adjuvant is used for the remaining immunizations. 6.8 Five female BALB / c mice aged 6 to 8 weeks were immunized with Chikungunya virus at TCID50 / mL by multiple subcutaneous injections in the back and groin, with an injection dose of 300 μL / mouse, and the immunization interval was 14 days. After four immunizations, blood was collected to determine the titer of polyclonal antibodies in the serum by IFA. When the titer reached the requirement, a booster immunization was performed 3 days before cell fusion.

[0024] Among them, Freund's adjuvant used a commercial product purchased from the market.

[0025] (3) Detection of mouse serum titer

[0026] Select Vero cells (African green monkey kidney cells) with good growth status, add 500 times diluted Chikungunya virus solution according to the volume of culture medium, place in 37 ℃, 5% CO2 incubator for culture and observation; when more than half of the cells show lesions of cell rounding and about to fall off, digest with trypsin and transfer to 96-well cell culture plates, culture statically until the cells adhere to the wall, discard the supernatant, and wash twice with 1×PBS. Add -20 ℃ precooled methanol, 150 μL / well, fix at -20 ℃ for 20min, and discard the supernatant. Add 0.5% Triton X-100 (immunostaining permeation solution, prepared with PBS), 150 μL / well, permeate at room temperature for 10min, and discard the supernatant. Add blocking solution, 150 μL / well, 37 ℃ for more than 3h, discard the supernatant, and prepare the Chikungunya virus antigen plate. The serum to be tested was diluted with sample diluent in each well, 100 μL / well, the dilution gradient range was 1:400~1:51200, 100 μL / well, 37℃2h or 4℃ overnight. Washed 4 times with PBST, 300 μL / well. FITC-goat anti-mouse IgG was diluted 300 times with sample diluent, 30 μL / well, 37℃1h. Washed 4 times with PBST, 300 μL / well, rinsed with running water for 5 minutes, dried in a 37℃ constant temperature box, and observed the fluorescence intensity under a fluorescence microscope.

[0027] (4) Hybridoma cell preparation

[0028] Discard the SP2 / 0 cell culture medium, add PBS to wash the cells, and then add trypsin to digest for 1 minute. Use a sterile rubber-tipped dropper to gently blow off the SP2 / 0 cells, add DMEM culture medium to transfer the cell suspension to a 50mL centrifuge tube, centrifuge at 1300rpm for 5 minutes, discard the supernatant, and add 20mL DMEM culture medium to resuspend the cells. Take 10μL of the cell suspension and mix it evenly with 10μL 0.4% trypan blue staining solution and 80μL DMEM culture medium. Take 10μL to count the cells using a cell counter. The number of SP2 / 0 cells required for cell fusion is approximately 2.0×10 7 ~5.0×10 7 indivual.

[0029] On the 4th day after booster immunization, the eyeballs of mice were removed for blood collection. After standing in a 37°C incubator for 1 hour, the blood was centrifuged at 5000rpm for 5 minutes to separate the serum. The mice were killed by cervical dislocation and immersed in 75% ethanol for body surface disinfection. The abdominal cavity of the mice was exposed and the spleen was aseptically removed. The spleen was placed on a sieve and ground after the surrounding connective tissue of the spleen was removed. The spleen cells were washed with DMEM medium and prepared into a single cell suspension. The suspension was centrifuged at 1300rpm for 5 minutes and the supernatant was discarded. The bottom of the centrifuge tube was flicked and the cells were resuspended with DMEM medium. The cells were counted by trypan blue staining. The number of mouse spleen cells was approximately 1.0×10 8 ~2.0×108 indivual.

[0030] SP2 / 0 cells and mouse spleen cells were mixed in a ratio of 1:4, centrifuged at 1300rpm for 5min, the supernatant was discarded, and the bottom of the centrifuge tube was flicked with a finger to disperse the cell clusters. 10mL of electrofusion buffer was added to resuspend the cells, centrifuged at 1300rpm for 5min, and the supernatant was discarded. 0.8mL of electrofusion buffer was added to resuspend the cells, and the cell suspension was slowly added to the electrode tank. The resistance was measured with an electrofusion instrument to ensure that the resistance value was between 6000 and 12000Ω. If the resistance value was too low, part of the cell suspension was aspirated. Click "Start" on the electrofusion instrument operation area to perform electrofusion. After 10 to 20s, the fusion was completed. All the cell suspension in the electrode tank was gently transferred to a 15mL centrifuge tube containing 1.6mL DMEM culture medium preheated at 37℃, and allowed to stand in a 37℃ water bath for 10min. The tube was centrifuged at 1300rpm for 5min, and the supernatant was discarded. Tap the bottom of the centrifuge tube with your fingers to disperse the cells, add an appropriate amount of DMEM medium containing HAT to resuspend the cells, gently pipette to evenly disperse the cells, and plate 200 μL / well into 10 96-well cell culture plates. Culture at 37°C and replace half of the medium with HT medium after 7 to 10 days.

[0031] (5) Screening, identification and subcloning of positive hybridoma cells

[0032] After cell fusion, observe the cell growth status under a microscope every day. When the hybridoma cells grow into clones and occupy 1 / 3 of the wells after about 10 days, use the IFA method to screen the positive clones of the hybridoma cell plate. Add 50μL sample diluent and 50μL cell supernatant to the previously prepared antigen plate, respectively, and incubate at 37℃ for 2h or 4℃ overnight. Wash 4 times with PBST, 300μL / well. FITC-goat anti-mouse IgG is diluted 300 times with sample diluent, 30μL / well, 37℃ for 1h. Wash 4 times with PBST, 300μL / well, rinse with running water for 5min after washing, dry in a 37℃ incubator, and observe the fluorescence intensity under a fluorescence microscope. Transfer part of the positive clone wells to a 24-well cell plate for continued culture, and use the limiting dilution method for subcloning. Use HT culture medium to continuously dilute the hybridoma cells in a 96-well plate, first dilute vertically from A1 to H1, then dilute horizontally from left to right in each column, add culture medium and place incubator for culture. Culture for about 14 days, during which the cell growth of each plate is observed, and wells with less than three clones, especially monoclonal wells, are selected for re-inspection. Re-inspect the 24-well plate when the hybridoma cells grow to 50% to 60% of the bottom area of ​​the plate. In order to ensure the uniformity of monoclonal, it is generally necessary to perform 3 to 5 limiting dilution subclones on the screened positive monoclonal cell lines. The final positive monoclonal cell lines are expanded and cultured and then frozen in liquid nitrogen.

[0033] (6) Ascites preparation and purification

[0034] Ascites was prepared by in vivo induction method. 8-week-old BALB / c female mice were intraperitoneally injected with 0.5 mL of sterile liquid paraffin. After 7 days, the positive hybridoma cells were washed with sterile PBS, digested with trypsin, centrifuged at 1300 rpm for 5 min, the supernatant was discarded, and the cells were resuspended with 1.5 mL of PBS and intraperitoneally injected into mice. Each mouse was intraperitoneally injected with 0.5 mL, and the number of cells was about 1.0×10 6 The mental state of the mice and the production of ascites were observed every day. When the abdomen of the mice was obviously swollen and the abdominal skin was tense, the ascites was collected. The collected ascites was centrifuged at 10,000 rpm for 10 minutes, the supernatant was separated, and the ascites antibody titer was determined by ELISA. The remaining ascites was packaged and stored at -80°C for later use.

[0035] Ascites was purified by ammonium sulfate precipitation and affinity chromatography. The purity of the purified monoclonal antibody was determined by SDS-PAGE (polyacrylamide gel electrophoresis). The monoclonal antibody Ig subtype was determined according to the instructions of Pierce Rapid ELISA MousemAb Isotyping Kit.

[0036] Compared with the prior art, the advantages and beneficial effects of the present invention are as follows:

[0037] The present invention obtains Chikungunya virus monoclonal antibody hybridoma cell line 9G8 and its monoclonal antibody by the above method, and the purified antibody is used for ELISA, indirect immunofluorescence method and qRT-PCR to prove its neutralization effect on Chikungunya virus. The anti-CHIKV monoclonal antibody secreted by this hybridoma cell line can provide powerful technical and product support for the diagnosis, quarantine, detection and epidemiological investigation of CHIKV.

[0038] The invention prepares hybridoma cells by electrofusion after immunizing BALB / c mice with chikungunya virus, and screens a monoclonal antibody with high specificity and high affinity to chikungunya virus by indirect immunofluorescence method and limiting dilution method. Neutralization test shows that the monoclonal antibody has a neutralizing effect on chikungunya virus. BRIEF DESCRIPTION OF THE DRAWINGS

[0039] Figure 1 This is the indirect immunofluorescence identification result of the monoclonal antibody 9G8 of the present invention.

[0040] Figure 2 This is the result of SDS-PAGE test of the ascites purification of monoclonal antibody 9G8 of the present invention. Figure 2 M in is the molecular weight of the standard protein; Figure 2 1 in the figure is the initially pure sample; Figure 2 2 in the figure is the permeate; Figure 23 in it is a washing liquid; Figure 2 4 to 6 are eluents.

[0041] Figure 3 This is the RT-qPCR test result of the neutralization effect of the monoclonal antibody 9G8 of the present invention. The asterisk in the figure represents a significant difference compared with the NC group, **** means P < 0.0001.

[0042] Figure 4 The results of the neutralization evaluation of the monoclonal antibody 9G8 in ascites at different dilutions of the present invention are ascites neutralization results. Figure 4 a to f in the figure are the results of chikungunya virus monoclonal antibody 9G8 prepared by hybridoma cell 9G8 at 1:200, 1:400, 1:800, 1:1600, 1:3200, 1:6400 dilutions and chikungunya virus at 1:10000 dilution in ascites; Figure 4 g in the figure is the negative control; Figure 4 h in the figure is the positive control.

[0043] Figure 5 The results are the evaluation results of the neutralization effect of monoclonal antibody 9G8 ascites on chikungunya virus of different dilutions. Figure 5 a to e in the figure are the results of 9G8 ascites diluted 1:200 neutralizing Chikungunya virus diluted 1:10000, 1:5000, 1:2500, 1:1000, and 1:500 respectively; Figure 5 f in the figure is the negative control. DETAILED DESCRIPTION

[0044] In order to make the present invention easier to understand, the present invention is further described below in conjunction with specific examples. It should be understood that these examples are only used to illustrate the present invention and are not used to limit the scope of the present invention.

[0045] Example 1 Preparation and identification of monoclonal antibodies

[0046] (1) Virus rejuvenation

[0047] The Chikungunya virus liquid preserved in the laboratory was diluted 100 times and inoculated into the brain of 3-day-old Kunming suckling mice at a dose of 20 μL / mouse. The suckling mice were observed for symptoms of hunched back, hind limb paralysis, and decreased activity. When the suckling mice were dying, they were killed, and the brains were dissected and taken out. Each brain was fully ground with 1 mL of PBS, and the supernatant was centrifuged to obtain the Chikungunya virus liquid rejuvenated by the mouse brain.

[0048] (2) Immunization of BALB / c mice

[0049] In order to obtain the best immunization effect, the Chikungunya virus liquid and Freund's adjuvant need to be fully mixed and emulsified before immunization. Freund's complete adjuvant is used for the first immunization, and Freund's incomplete adjuvant is used for the remaining immunizations. 6.8 Five female BALB / c mice aged 6 to 8 weeks were immunized with Chikungunya virus at TCID50 / mL by multiple subcutaneous injections in the back and groin, with an injection dose of 300 μL / mouse, and the immunization interval was 14 days. After four immunizations, blood was collected to determine the titer of polyclonal antibodies in the serum by IFA. When the titer reached the requirement, a booster immunization was performed 3 days before cell fusion.

[0050] Among them, Freund's adjuvant used a commercial product purchased from the market.

[0051] (3) Detection of mouse serum titer

[0052] Select Vero cells (African green monkey kidney cells) with good growth status, add 500 times diluted Chikungunya virus solution according to the volume of culture medium, place in 37 ℃, 5% CO2 incubator for culture and observation; when more than half of the cells show lesions of cell rounding and about to fall off, digest with trypsin and transfer to 96-well cell culture plates, culture statically until the cells adhere to the wall, discard the supernatant, and wash twice with 1×PBS. Add -20 ℃ precooled methanol, 150 μL / well, fix at -20 ℃ for 20min, and discard the supernatant. Add 0.5% Triton X-100 (immunostaining permeation solution, prepared with PBS), 150 μL / well, permeate at room temperature for 10min, and discard the supernatant. Add blocking solution (purchased from Huzhou Yingchuang Biotechnology Co., Ltd.), 150 μL / well, 37 ℃ for more than 3h, discard the supernatant, and prepare the Chikungunya virus antigen plate. The serum to be tested was diluted with sample diluent in each well, 100 μL / well, the dilution gradient range was 1:400-1:51200, 100 μL / well, 37℃2h or 4℃ overnight. Washed 4 times with PBST, 300 μL / well. FITC-goat anti-mouse IgG was diluted 300 times with sample diluent (purchased from Huzhou Yingchuang Biotechnology Co., Ltd.), 30 μL / well, 37℃1h. Washed 4 times with PBST, 300 μL / well, rinsed with running water for 5 minutes, dried in a 37℃ constant temperature box, and observed the fluorescence intensity under a fluorescence microscope.

[0053] (4) Hybridoma cell preparation

[0054] Discard the SP2 / 0 cell culture medium, add PBS to wash the cells, and then add trypsin to digest for 1 minute. Use a sterile rubber-tipped dropper to gently blow off the SP2 / 0 cells, add DMEM culture medium to transfer the cell suspension to a 50mL centrifuge tube, centrifuge at 1300rpm for 5 minutes, discard the supernatant, and add 20mL DMEM culture medium to resuspend the cells. Take 10μL of the cell suspension and mix it evenly with 10μL 0.4% trypan blue staining solution and 80μL DMEM culture medium. Take 10μL to count the cells using a cell counter. The number of SP2 / 0 cells required for cell fusion is approximately 2.0×10 7 ~5.0×10 7 indivual.

[0055] On the 4th day after booster immunization, the eyeballs of mice were removed for blood collection. After standing in a 37°C incubator for 1 hour, the blood was centrifuged at 5000rpm for 5 minutes to separate the serum. The mice were killed by cervical dislocation and immersed in 75% ethanol for body surface disinfection. The abdominal cavity of the mice was exposed and the spleen was aseptically removed. The spleen was placed on a sieve and ground after the surrounding connective tissue of the spleen was removed. The spleen cells were washed with DMEM medium and prepared into a single cell suspension. The suspension was centrifuged at 1300rpm for 5 minutes and the supernatant was discarded. The bottom of the centrifuge tube was flicked and the cells were resuspended with DMEM medium. The cells were counted by trypan blue staining. The number of mouse spleen cells was approximately 1.0×10 8 ~2.0×10 8 indivual.

[0056] Mix SP2 / 0 cells and mouse spleen cells in a ratio of 1:4, centrifuge at 1300rpm for 5min, discard the supernatant, and flick the bottom of the centrifuge tube with your fingers to disperse the cell clusters. Add 10mL of electrofusion buffer to resuspend the cells, centrifuge at 1300rpm for 5min, and discard the supernatant. Add 0.8mL of electrofusion buffer to resuspend the cells, and slowly add the cell suspension to the electrode tank to avoid bubbles affecting the resistance. Measure the resistance with an electrofusion instrument to ensure that the resistance value is between 6000 and 12000Ω. If the resistance value is too low, aspirate some of the cell suspension. Click "Start" on the electrofusion instrument operation area to perform electrofusion. After 10 to 20 seconds, the fusion is completed. Gently transfer all the cell suspension in the electrode tank to a 15mL centrifuge tube containing 1.6mL DMEM culture medium preheated at 37℃, let it stand in a 37℃ water bath for 10min, centrifuge at 1300rpm for 5min, and discard the supernatant. Tap the bottom of the centrifuge tube with your finger to disperse the cells, add 120 mL of DMEM medium containing HAT to resuspend the cells, gently pipette to evenly disperse the cells, and plate 200 μL / well into 6 96-well cell culture plates. Culture at 37°C and replace half of the medium with HT medium after 7 to 10 days.

[0057] (5) Screening, identification and subcloning of positive hybridoma cells

[0058] After cell fusion, observe the cell growth status under a microscope every day. When the hybridoma cells grow into clones and occupy 1 / 3 of the wells after about 10 days, use the IFA method to screen the positive clones of the hybridoma cell plate. Add 50μL sample diluent and 50μL cell supernatant to the previously prepared antigen plate, respectively, and incubate at 37℃ for 2h or 4℃ overnight. Wash 4 times with PBST, 300μL / well. FITC-goat anti-mouse IgG is diluted 300 times with sample diluent, 30μL / well, 37℃ for 1h. Wash 4 times with PBST, 300μL / well, rinse with running water for 5min after washing, dry in a 37℃ incubator, and observe the fluorescence intensity under a fluorescence microscope. Transfer part of the positive clone wells to a 24-well cell plate for continued culture, and use the limiting dilution method for subcloning. Use HT culture medium to continuously dilute the hybridoma cells in a 96-well plate, first dilute vertically from A1 to H1, then dilute horizontally from left to right in each column, add culture medium and place incubator for culture. The culture was continued for about 14 days, during which the growth of cells in each plate was observed. Wells with less than three clones, especially monoclonal wells, were selected for re-inspection. The 24-well plate was re-inspected when the hybridoma cells grew to 50% to 60% of the bottom area of ​​the plate. The positive monoclonal cells were selected and subcloned 3 to 5 times in the same way until the supernatant of all wells of the cells was positive and the OD values ​​of each well were close. The positive monoclonal cell line was expanded and frozen, and the hybridoma cell line that stably secreted monoclonal antibodies was named 9G8. The results are as follows Figure 1 As shown, the monoclonal antibody secreted by the prepared hybridoma cell 9G8 can recognize Chikungunya virus.

[0059] (6) Ascites preparation and purification

[0060] Ascites was prepared by in vivo induction method. 8-week-old BALB / c female mice were intraperitoneally injected with 0.5 mL of sterile liquid paraffin. After 7 days, the positive hybridoma cells were washed with sterile PBS, digested with trypsin, centrifuged at 1300 rpm for 5 min, the supernatant was discarded, and the cells were resuspended with 1.5 mL of PBS and intraperitoneally injected into mice. Each mouse was intraperitoneally injected with 0.5 mL, and the number of cells was about 1.0×10 6 The mental state of the mice and the production of ascites were observed every day. When the abdomen of the mice was obviously swollen and the abdominal skin was tense, the ascites was collected. The collected ascites was centrifuged at 10,000 rpm for 10 minutes, the supernatant was separated, and the ascites antibody titer was determined by ELISA. The remaining ascites was packaged and stored at -80°C for later use.

[0061] Ascites purification was performed by ammonium sulfate precipitation with caprylic acid and further purification by affinity chromatography. The purity of the purified monoclonal antibody was 95% as determined by SDS-PAGE (polyacrylamide gel electrophoresis). Figure 2As shown in the figure, two bands can be detected after the purified ascites antibody, namely the antibody heavy chain with a size of about 50 kDa and the antibody light chain with a size of about 25 kDa. The concentration of the purified antibody was determined by a nucleic acid protein analyzer to be 3.457 mg / mL.

[0062] Example 2 Characterization of Monoclonal Antibodies

[0063] (1) Identification of monoclonal antibody Ig subtypes

[0064] Identify the monoclonal antibody Ig subtype according to the instructions of Pierce Rapid ELISA Mouse mAb Isotyping Kit. Dilute the culture supernatant of the screened positive monoclonal cells with TBS 10 times, add 50 μL per well to the ELISA plate provided by the kit, then add 50 μL of each type of HRP-labeled antibody, gently shake the ELISA plate to mix, place at room temperature for 1 hour, wash 3 times with PBST, add 75 μL of TMB substrate solution to each well for color development, add 75 μL of stop solution to each well after 10-15 minutes, and measure OD with an enzyme reader. 450 The results showed that the subtype of the monoclonal antibody secreted by 9G8 was IgG2a, and the light chain was κ chain.

[0065] (2) Identification of monoclonal antibody specificity

[0066] The established IFA method was used to identify the reactivity of positive monoclonal antibodies with alphavirus and flavivirus, and antigen plates of CHIKV, Mayaro virus (MAYV), Semenlik virus (SFV), Sindbis virus (SINV), forest encephalitis virus (TBEV), Zika virus (ZIKV), West Nile virus (WNV), yellow fever virus (YFV), dengue virus 1-4 (DENV1-4), Japanese encephalitis virus (JEV) and uninfected Vero cells were prepared. The positive monoclonal cell culture supernatant and sample diluent were mixed 1:1 and added to the antigen plates of different viruses, 100 μL / well, and placed at 37℃ for 2h or 4℃ overnight. The positive control was the polyclonal antibody of each virus, diluted 1:500 in the sample diluent, and the negative control was the SP2 / 0 cell culture supernatant. Wash 4 times with PBST, 300 μL / well. FITC-goat anti-mouse IgG was diluted 300 times with sample diluent, 30 μL / well, 37°C for 1h. Washed 4 times with PBST, 300 μL / well, rinsed with running water for 5 min after washing, dried in a 37°C incubator, and observed the fluorescence intensity under a fluorescence microscope. The specific identification results of monoclonal antibody 9G8 are shown in Table 1. There is no cross reaction with the tested virus strains, indicating that the 9G8 monoclonal antibody has high specificity for Chikungunya virus.

[0067] Table 1 Specificity identification results of 9G8 monoclonal antibody

[0068]

[0069] (3) Evaluation of monoclonal antibody neutralization effect

[0070] Take the well-growing Vero cells from the T75 cell culture flask, wash them with sterile PBS, and then add trypsin to digest for 1 min. Blow off the cells with a rubber-tipped pipette, add 15 mL of DMEM medium containing 10% FBS to terminate the digestion, centrifuge at 1300 rpm for 5 min, and discard the supernatant. Add complete medium to resuspend the cells, and then quantitatively plate them in 24-well cell plates and 96-well cell plates after trypan blue staining and counting. The number of cells in the 24-well plate is about 1.0×10 5 The number of cells in a 96-well plate is approximately 3.0×10 4 The cells were cultured in a CO2 incubator overnight.

[0071] The next day, GFP-labeled CHIKV was diluted 1:10000 in DMEM medium containing 2% FBS, 1:20 diluted 9G8 hybridoma cell culture supernatant was added to the 24-well plate, 1:200, 1:400, 1:800, 1:1600, 1:3200, and 1:6400 diluted 9G8 monoclonal antibody ascites were added to the 96-well plate, the positive control was 1:2000 diluted CHIKV immune mouse serum (mouse serum needs to be incubated in a 37°C water bath for 30 minutes to inactivate complement components before mixing with the virus solution), and the negative control was 1:10 diluted SP2 / 0 cell culture supernatant, which was incubated in a 37°C water bath for 1 hour. The culture medium in the cell plate wells was discarded, and the monoclonal antibody-virus mixture was added to 1 mL / well of the 24-well plate and 200 μL / well of the 96-well plate, with 3 replicates per group. After culturing in a 37°C incubator for 2 hours, the supernatant was discarded and replaced with 2% FBSDMEM culture medium for further culturing for 36 hours. The 24-well plate was lysed to extract viral RNA and the neutralization effect of the monoclonal antibody was quantitatively detected by RT-qPCR.

[0072] The complete genome sequences of various epidemic strains of CHIKV were retrieved in GenBank. Primers and probes were designed for the conserved regions of the CHIKV gene using Primer Premier 6.0 software, and BLAST specificity verification was performed. The primers and probes were synthesized by Shanghai Sangon Biotechnology Co., Ltd. The information of CHIKV primers and probes is shown in Table 2.

[0073] Table 2 CHIKV primer and probe information

[0074]

[0075] After RNA was extracted by Trizol method, the neutralization effect of monoclonal antibody 9G8 cell supernatant was detected according to the RT-qPCR reaction system shown in Table 3 and the reaction procedure shown in Table 4. The results are shown in Figure 3 As shown, compared with the negative control group (NC), the relative expression level of CHIKV in the hybridoma cell supernatant was significantly reduced (P < 0.001), indicating that the 9G8 monoclonal antibody has a neutralizing effect on CHIKV.

[0076] Table 3 RT-qPCR reaction system

[0077]

[0078]

[0079] Table 4 RT-qPCR reaction procedure

[0080]

[0081] The green fluorescence of the 96-well plate was observed by fluorescence microscope, and the green fluorescence image of the whole well was scanned by cell imaging. Figure 4 As shown, the neutralization titer of 9G8 monoclonal antibody ascites reached 1:3200.

[0082] The neutralization titer of 9G8 monoclonal antibody ascites against CHIKV was evaluated. Vero cells were plated in 96-well plates. The next day, 1:200 diluted 9G8 monoclonal antibody ascites was mixed with 1:10000, 1:5000, 1:2500, 1:1000, and 1:500 diluted CHIKV, respectively. The rest of the steps were the same as above. The results are shown in Figure 2. Figure 5 As shown, the neutralization titer of 9G8 monoclonal antibody ascites against CHIKV reached 1:1000.

[0083] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the essence and scope of the technical solution of the present invention.

Claims

1. A hybridoma cell line, characterized in that The hybridoma cell line is CHIKV mAb 9G8, which was deposited in the China Center for Type Culture Collection on April 23, 2024, with the deposit number CCTCC NO: C2024122, and the deposit address is Wuhan University, Wuhan, China.

2. A monoclonal antibody against Chikungunya virus, characterized in that: The monoclonal antibody is secreted and produced by the hybridoma cell line CHIKV mAb 9G8 according to claim 1.

3. The method for preparing monoclonal antibodies against Chikungunya virus according to claim 2, characterized in that: The following steps are involved: (1) BALB / c mice are immunized with Chikungunya virus to obtain immune BALB / c mice; (2) Spleen cells of immunized mice were taken and fused with mouse myeloma cells SP2 / 0. After fusion, the cells were selectively cultured in HAT selection medium, positive clones were screened by indirect immunofluorescence method, and hybridoma cells in positive wells were cloned and cultured by limiting dilution method until the antibody positivity rate of cloned cells reached 100%, thereby obtaining hybridoma cell lines; (3) The hybridoma cell line obtained in step (2) is transplanted into the peritoneal cavity of mice for culture, the ascites is collected, and the purified monoclonal antibody is obtained using the ammonium sulfate method and affinity chromatography.

4. The preparation method according to claim 3, characterized in that: The purity of the purified monoclonal antibody reached 95%.

5. The preparation method according to claim 3, characterized in that: The subtype of the monoclonal antibody is IgG2a.

6. Use of the monoclonal antibody against chikungunya virus according to claim 2 or the monoclonal antibody prepared by the preparation method according to claim 3 in preparing a reagent for detecting chikungunya virus or in preparing a reagent for diagnosing and / or judging the prognosis of chikungunya disease.

7. A reagent for detecting Chikungunya virus, characterized in that The reagent comprises the monoclonal antibody against Chikungunya virus according to claim 2 or the monoclonal antibody prepared by the preparation method according to claim 3.

8. A reagent for diagnosis and / or prognosis of Chikungunya fever, characterized in that: The reagent comprises the monoclonal antibody against Chikungunya virus according to claim 2 or the monoclonal antibody prepared by the preparation method according to claim 3.

9. Use of the monoclonal antibody against chikungunya virus according to claim 2 or the monoclonal antibody prepared by the preparation method according to claim 3 in preparing a preparation for treating chikungunya fever.

10. A biological agent for treating Chikungunya fever, characterized in that: The biological agent comprises the monoclonal antibody against Chikungunya virus according to claim 2 or the monoclonal antibody prepared by the preparation method according to claim 3.

Citation Information

Patent Citations

  • Antibody-mediated neutralization of chikungunya virus

    CN107708726A

  • Immunodiagnosis kit for specifically detecting chikungunya virus NSP1 antigen

    CN111398585A

  • Anti-chikv antibodies and uses thereof

    WO2018073387A1